Get started
ARDELYX, INCAA

ARDELYX, INC

108.00MXND
−39.20−26.63%
At close at Jan 17, 20:13 GMT
MXN
No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Forecast Seasonals

ARDX trade ideas

ARDX Channel breakout NASDAQ:ARDX Channel break is all based on business performance. If good Q3 ER = 60+mm rev// neg .05-.07 eps (27-X/35-I/ 3-ect ) then breakout. If neutral or flatish growth, then more development, sales, and catalyst needed.. develops into Elliot 5 wave in the channel. Could break on good #4 too, but at year end ER around FEB 2025 becomes the pinnacle. If further positive development it breaks out above. If business doesn't materialize and continued losses, then breakdown to previous channel - becomes a head n shoulder macro chart (very unlikely btw)..(it's not the chart that determines movement, it's the business) Most of this board's revenue projections and growth outlook is spot on. Fully positioned for break on #3..
NLong
by jdon1117
1
ARDX Ardelyx Options Ahead of Earnings If you haven`t bought ARDS before it went up 6X: Then analyzing the options chain and the chart patterns of ARDX Ardelyx prior to the earnings report this week, I would consider purchasing the 4usd strike price Calls with an expiration date of 2024-1-19, for a premium of approximately $0.45. If these options prove to be profitable prior to the earnings release, I would sell at least half of them. Looking forward to read your opinion about it.
NLong
by TopgOptions
Focus on Biotechnology: Ardelyx Inc. Trading Idea for 19/10/2023Biotechnology company Ardelyx Inc. has received FDA approval for its drug Xphozah. This medication is intended for treating kidney diseases and is typically recommended for patients with elevated kidney phosphorus levels. Xphozah could be a valuable addition to hemodialysis therapy since it is compatible with other drugs used for treating these conditions. Let's take a look at the Ardelyx Inc (NASDAQ: ARDX) stock chart. On the D1 timeframe, support has formed at 3.22, with resistance at 4.24. A break in the downward trend is very likely. On the H1 timeframe, the short-term target for the price increase is around 5.53; while in the medium term, it could reach 9.21. — Ideas and other content presented on this page should not be considered as guidance for trading or an investment advice. RoboMarkets bears no responsibility for trading results based on trading opinions described in these analytical reviews. The material presented and the information contained herein is for information purposes only and in no way should be considered as the provision of investment advice for the purposes of Investment Firms Law L. 87(I)/2017 of the Republic of Cyprus or any other form of personal advice or recommendation, which relates to certain types of transactions with certain types of financial instruments. Risk Warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67.85% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
N
by RoboMarkets
730% upside stock according to CitigroupArdelyx , Inc. ARDX had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year. Since ARDX’s Market Cap is only 191.663Mil, it has still a big upside potential. A decent 9X revenue means a potential 4.5 Billion market cap. That`s why in the last 2 days we saw volumes higher than 100Mil. Recently, on 11/30/2021, Yigal Nochomovitz from Citigroup Boosted the Price Target from Positive to Buy increasing the price target from $7.00 to $13.00. The price of the stock is now 1.7usd. My valuation is much higher! I look forward to read your opinion about it.
NLong
by TopgOptions
7
$ARDX Support and ResistanceArdelyx shares are trading higher after Ladenburg Thalmann upgraded the stock from Neutral to Buy and announced a $6 price target. Also, Citigroup maintained a Buy rating and raised its price target from $7 to $13. Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
NLong
by BADQOMOCAWGOWLD
ARDX 500mil Revenue Forecasts for a Penny Stock | The 10X call??Ardelyx, Inc. ARDX yesterday had one of the the highest the out of the money call options, due to the fact they plan to launch IBSRELA, the company's FDA approved treatment for irritable bowel syndrome with constipation (IBS-C) in adults, in the second quarter of 2022, that has a potential peak in revenue greater than 500mil per year. Since ARDX’s Market Cap is only 191.663Mil, it has still a big upside potential. A decent 9X revenue means a potential 4.5 Billion market cap. That`s why in the last 2 days we saw volumes higher than 100Mil. Recently, on 11/30/2021, Yigal Nochomovitz from Citigroup Boosted the Price Target from Positive to Buy increasing the price target from $7.00 to $13.00. The price of the stock is now 1.7usd. My valuation is much higher! I look forward to read your opinion about it.
NLong
by TopgOptions
1
ARDX Post Sell-Off ANALysisFollowing the negative news that sent this stock into an 82% tailspin there is no viable buy signal aside from a simple long-term play. Trend is continuing downward slowly. Has yet to find a solid support zone. By way of Analyst Consensus, upside is above 100% but may take 12-months to materialize. By way of previous share price average, upside is close to 500%. Not likely to happen within a year. Ultimately, this stock needs a strong positive Catalyst. Another negative Catalyst will undoubtedly send this stock below $1. I believe this is a good long-term play for 100% or better, just don't stare at the ticker too long.
NLong
by Solomon1983
2